EUVIMEDDescoperă EUVIMED
Vergleichsstudie

Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study

Dana Dlouha iD, Petr Pompach, Jana Horackova, Jaroslav Alois Hubacek, Vladimir Blaha

PROTEOMICS – Clinical Applications · 2026-05 · 20 (3)

DOI: 10.1002/prca.70043 ↗

At a glance

Vergleichsstudie in PROTEOMICS – Clinical Applications, published online on 2026-03-29. Written by Dana Dlouha and 4 co-authors. Institution: Center For Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic. Major MEDLINE topics: PCSK9 Inhibitors, Hyperlipoproteinemia Type II, Proteome. Cited 1 times so far (Crossref); 66 references. Funded by: Ministry of Health of the Czech Republic, Czech Health Research Council, Ministerstvo Zdravotnictví Ceské Republiky.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a novel approach for reducing low‐density lipoprotein cholesterol (LDL‐C) levels in patients with familial hypercholesterolemia (FH). In our study, we aimed to compare the plasma proteome profiles of heterozygous FH (HeFH) patients and non‐FH patients treated with PCSK9 inhibitors (PCSK9i).

Methods

We analyzed 132 plasma samples from 38 patients. Samples were collected before the start of the PCSK9i treatment and then again at the third, sixth, and 12 th months of treatment. Using LC‒MS technology, we compared two approaches: depleted and nondepleted samples.

Results

Across all time points of treatment, numerous differentially expressed proteins were detected regardless of the FH status compared to baseline. We identified only three proteins with downregulated expression—PCSK9, CRTAC1, and PON1—with p adj

Subjects

MeSH terms (MEDLINE)

PCSK9 InhibitorsHyperlipoproteinemia Type IIProteomeHumansPilot ProjectsFemaleMaleMiddle AgedProprotein Convertase 9AdultProteomics

Author keywords

PCSK9familial hypercholesterolemiaplasmaproteome

Substances

PCSK9 InhibitorsProteomeProprotein Convertase 9PCSK9 protein, human

Authors and institutions

  • Center For Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
  • Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
  • Department of Clinical Biochemistry, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
  • First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Faculty of Medicine, Charles University, Hradec Králové, Czech Republic.
  • 3rd Department of Internal Medicine - Metabolism and Gerontology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.

ORCID profiles: Dana Dlouha

Funding

  • Ministry of Health of the Czech Republic
  • Czech Health Research Council
  • Ministerstvo Zdravotnictví Ceské Republiky
  • Agentura Pro Zdravotnický Výzkum České Republiky

Cite

APA

Dlouha, D., Pompach, P., Horackova, J., Hubacek, J. A., & Blaha, V. (2026). Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study. PROTEOMICS – Clinical Applications, 20(3). https://doi.org/10.1002/prca.70043

Vancouver

Dlouha D, Pompach P, Horackova J, Hubacek JA, Blaha V. Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study. PROTEOMICS – Clinical Applications. 2026;20(3). doi:10.1002/prca.70043

BibTeX
@article{Dlouha2026,
  author = {Dlouha, Dana and Pompach, Petr and Horackova, Jana and Hubacek, Jaroslav Alois and Blaha, Vladimir},
  title = {Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2026},
  volume = {20},
  number = {3},
  doi = {10.1002/prca.70043}
}
Start for free →